We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ARAB HEALTH - INFORMA

Download Mobile App





COVID-19 Vaccine Developers to Issue Joint Public Pledge Against Premature Launch Before Proving Safety and Effectiveness

By HospiMedica International staff writers
Posted on 07 Sep 2020
Print article
Illustration
Illustration
Several developers of COVID-19 vaccines are coming together to issue a public pledge against seeking government approval until their candidates prove to be safe and effective, in a move to reassure the public that they will not compromise scientific, regulatory rigor amidst the urgency to develop a coronavirus vaccine.

According to a report by The Wall Street Journal (WSJ), vaccine makers including Pfizer Inc. (New York, NY, USA), Johnson & Johnson (New Brunswick, NJ, USA) and Moderna, Inc. (Cambridge, MA, USA) are finalizing the draft of the joint statement that commits to making the safety and well-being of vaccinated people their priority. The companies will also pledge to adhere to high scientific and ethical standards in the conduct of clinical studies and in their manufacturing processes. According to the draft statement, the vaccine makers will submit applications for Emergency Use Authorization (EUA) to the US Food and Drug Administration (FDA) or licensure of vaccines based on “substantial evidence of safety and efficacy” from Phase 3 clinical trials being conducted under the FDA’s guidance.

“We believe this pledge will help ensure public confidence in the COVID-19 vaccines that may ultimately be approved and adherence to the rigorous scientific and regulatory process by which they are evaluated,” says the draft statement, as mentioned in the WSJ report.

Separately, speaking at an online press briefing organized by the International Federation of Pharmaceutical Manufacturers and Associations (IFPMA), Pfizer’s Chief Executive Albert Bourla said, “We will never ourselves submit for authorization or approval any vaccine before we feel it is safe and effective. We will not cut corners.”

At the IFPMA event, rival Merck’s Chief Executive Kenneth Frazier also assured that safety remained their top priority and said, “We all understand the need to move with urgency given the pandemic, but we will not sacrifice safety under any set of circumstances.”

Related Links:
Pfizer Inc.
Johnson & Johnson
Moderna, Inc.


Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
New
Pneumatic Stool
Avante 5-Leg Pneumatic Stool
New
LED Surgical Light
Convelar 1670 LED+/1675 LED+/1677 LED+

Print article

Channels

Surgical Techniques

view channel
Image: The new treatment combination for subdural hematoma reduces the risk of recurrence (Photo courtesy of Neurosurgery 85(6):801-807, December 2019)

Novel Combination of Surgery and Embolization for Subdural Hematoma Reduces Risk of Recurrence

Subdural hematomas, which occur when bleeding happens between the brain and its protective membrane due to trauma, are common in older adults. By 2030, chronic subdural hematomas are expected to become... Read more

Patient Care

view channel
Image: The portable biosensor platform uses printed electrochemical sensors for the rapid, selective detection of Staphylococcus aureus (Photo courtesy of AIMPLAS)

Portable Biosensor Platform to Reduce Hospital-Acquired Infections

Approximately 4 million patients in the European Union acquire healthcare-associated infections (HAIs) or nosocomial infections each year, with around 37,000 deaths directly resulting from these infections,... Read more

Health IT

view channel
Image: First ever institution-specific model provides significant performance advantage over current population-derived models (Photo courtesy of Mount Sinai)

Machine Learning Model Improves Mortality Risk Prediction for Cardiac Surgery Patients

Machine learning algorithms have been deployed to create predictive models in various medical fields, with some demonstrating improved outcomes compared to their standard-of-care counterparts.... Read more

Point of Care

view channel
Image: The acoustic pipette uses sound waves to test for biomarkers in blood (Photo courtesy of Patrick Campbell/CU Boulder)

Handheld, Sound-Based Diagnostic System Delivers Bedside Blood Test Results in An Hour

Patients who go to a doctor for a blood test often have to contend with a needle and syringe, followed by a long wait—sometimes hours or even days—for lab results. Scientists have been working hard to... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.